- Lifecore Biomedical signed a CDMO manufacturing agreement for an established aesthetics product, including technical transfer and PPQ batches.
- The program is expected to generate commercial revenue within 24 months and marks the company’s third commercial site transfer since October 2025.
Lifecore Biomedical, Inc. has entered into a contract manufacturing agreement with a new aesthetics customer to support the production of an established, market-approved sterile product, the company said.
Under the agreement, the CDMO will conduct technical transfer activities, including process performance qualification (PPQ) batches, for a product currently manufactured in-house by the customer outside the United States. The outsourced manufacturing is intended to increase production capacity for the U.S. market.
The company expects the program could begin generating commercial revenue within 24 months. Lifecore said the agreement aligns with its broader strategy to focus on late-stage programs and commercial site transfers, which it views as offering a more predictable path to revenue compared with traditional development work.
This marks the third commercial site transfer agreement signed by Lifecore since October 2025. The company stated that such programs are part of its effort to expand into additional therapeutic modalities while strengthening its contract manufacturing pipeline.
“We are thrilled to announce the signing of our third commercial site transfer in a relatively short amount of time. We believe these high-value wins reflect Lifecore’s robust quality standards, strong compliance track record, as well as our proven ability to professionally meet the significant demands of commercial production.”
Paul Josephs, chief executive officer of Lifecore
